What are the latest funding news in the synthetic biology market? (July 2026)
Download our beautiful pitch about the synthetic biology market
In our synthetic biology market deck, you will find everything you need to understand the market
Synthetic biology funding in July 2026 showed a clear split between large therapeutic platforms and smaller tools that help teams design, read, or control biology.
The most recent disclosed deals were concentrated in engineered antimicrobials, CRISPR medicines, stem-cell programming, AI biology, protein design, and precision fermentation.
Across the latest 12 disclosed announcements, NewLimit dominated total capital with a $435M Series C, while early-stage software and bioprocess tools still filled most of the deal count.
And if you want to better understand this new industry, you can download our pitch covering the synthetic biology market.
Insights
- Therapeutics took the largest share of capital, mainly because NewLimit’s $435M Series C made epigenetic reprogramming the clear funding outlier in synthetic biology.
- Only 3 of the 12 latest deals were above $25M, which shows that synthetic biology funding was active but still selective outside large platform therapeutics.
- AI was present in at least 5 deals, from Ingenix and Scala Biodesign to Biographica, showing how biological design software is becoming a core synbio layer.
- Precision fermentation remained investable, but the recent rounds were smaller, with StrainX, Fermeate, and Clean Food Group focused on practical scale-up rather than pure discovery.
- CRISPR and gene-editing related companies appeared across health and agriculture, suggesting that programmable biology is spreading beyond human therapeutics.
- Europe had strong representation, with Spain, the UK, Poland, and Israel contributing multiple deals across antimicrobials, DNA design, AI biology, and protein engineering.
- The funding mix was broad, ranging from pre-seed to Series C, which suggests the synthetic biology market still has both early infrastructure creation and late-stage platform scaling.
- Non-dilutive capital mattered in this period, with Scribe’s CIRM award showing how public funding can accelerate high-risk CRISPR programs without traditional equity dilution.
As this chart shows, and as featured in our synthetic biology market deck, search interest in gene editing has grown significantly
Summary table of the latest funding deals in the synthetic biology market as of July 2026
We define the synthetic biology market as the set of tools, platforms, and products that rely on engineering biological systems using designed DNA, genetic circuits, or engineered organisms.
We include specialized synbio tools and software, biofoundry and automation platforms, and end-use applications in areas like food, agriculture, health, chemicals, and materials where synthetic biology is a core part of how the product is created or performs.
We exclude conventional biotech and pharmaceuticals, basic GMOs, and traditional fermentation or bio-based products where modern synthetic biology methods are not central to the design or production process.
You can also read our detailed analysis to understand how funding activity in the synthetic biology market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the synthetic biology market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Telum Therapeutics | 1 July 2026 | $19.4M | Series A | Engineered antimicrobial proteins |
| Houdini Bio | 26 June 2026 | $1.9M | Pre-seed plus grants | DNA design software |
| Syntax Bio | 22 June 2026 | $14.4M | Series A expansion | Cell programming & regenerative medicine |
| Scribe Therapeutics | 18 June 2026 | $25M+ | Non-dilutive award | CRISPR genetic medicines |
| Ingenix | 3 June 2026 | $14M | Seed extension | AI biology platform |
| NewLimit | 2 June 2026 | $435M | Series C | Epigenetic reprogramming therapeutics |
| StrainX Bioworks | 25 May 2026 | $13M | Series A | Precision-fermented biomolecules |
| Pumpkinseed | 5 May 2026 | $20M | Series A | Protein sequencing & biology data layer |
| Fermeate | 29 April 2026 | $2M | Seed | Optogenetic fermentation controls |
| Clean Food Group | 14 April 2026 | $6.1M | Not disclosed | Yeast-derived oils and fats |
| Scala Biodesign | 31 March 2026 | $16M | Series A | AI protein design software |
| Biographica | 7 January 2026 | $9.5M | Seed | Crop gene-editing design software |
All the latest funding deals during in the synthetic biology market as of July 2026
Telum Therapeutics raised $19.4M in July 2026
When was it?
The Series A was announced on 1 July 2026.
Who are they?
Telum Therapeutics develops biologically derived antimicrobial proteins using metagenomic data, synthetic biology, and generative AI to fight drug-resistant bacterial infections.
Geographical focus?
Telum Therapeutics is based in Spain and targets a global hospital market for severe drug-resistant infections.
Why do we include them in the synthetic biology market?
Telum Therapeutics fits the engineered antimicrobial proteins category because its platform designs biologically derived protein antimicrobials rather than conventional small-molecule antibiotics.
What is the company stage?
Telum Therapeutics is clinical-stage and is moving its lead hospital-acquired pneumonia program toward Phase 1.
How much did they raise?
Telum Therapeutics raised €18M, which is approximately $19.4M for this round.
What round is it?
The financing was a Series A round led by AMR Action Fund.
Why did they raise?
Telum Therapeutics raised to advance its lead Acinetobacter baumannii pneumonia program through Phase 1 and keep developing its antimicrobial pipeline.
Houdini Bio raised $1.9M in June 2026
When was it?
The financing was announced on 26 June 2026.
Who are they?
Houdini Bio builds software that redesigns therapeutic DNA so gene and cell therapies can avoid biological silencing and stay active longer.
Geographical focus?
Houdini Bio is a UK company based around the Cambridge biotech ecosystem and initially serves gene and cell therapy developers.
Why do we include them in the synthetic biology market?
Houdini Bio fits the DNA design software category because its platform engineers therapeutic genetic payloads with machine learning and sequence design.
What is the company stage?
Houdini Bio is at pre-seed stage and has just emerged from stealth with early platform validation work.
How much did they raise?
Houdini Bio raised about £1.5M, which is approximately $1.9M including grant funding and pre-seed investment.
What round is it?
The financing was a pre-seed round combined with non-dilutive grant funding.
Why did they raise?
Houdini Bio raised to validate and scale its DNA sequence design platform and begin building pharmaceutical partnerships.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Syntax Bio expanded its Series A to $14.4M in June 2026
When was it?
The Series A expansion was reported on 22 June 2026.
Who are they?
Syntax Bio programs stem cells with a CRISPR-based platform called Cellgorithm to create next-generation cell therapies and organoids.
Geographical focus?
Syntax Bio is based in Chicago and is focused on US-led therapeutic development with broader platform potential.
Why do we include them in the synthetic biology market?
Syntax Bio fits the cell programming category because its core technology controls stem-cell differentiation through a CRISPR-based biological programming system.
What is the company stage?
Syntax Bio is in early platform development and clinical-enabling work, with a diabetes program being built out.
How much did they raise?
Syntax Bio raised a $14.4M Series A expansion, bringing total funding to more than $25M.
What round is it?
The financing was an expanded Series A round.
Why did they raise?
Syntax Bio raised to expand operations, add leadership, and continue developing programmable cell therapy programs.
Scribe Therapeutics received more than $25M in June 2026
When was it?
The non-dilutive awards were announced on 18 June 2026.
Who are they?
Scribe Therapeutics engineers purpose-built CRISPR technologies for in vivo genetic medicines, starting with cardiometabolic disease.
Geographical focus?
Scribe Therapeutics is US-based and develops genetic medicines for large disease populations.
Why do we include them in the synthetic biology market?
Scribe Therapeutics fits the CRISPR genetic medicines category because its core work is engineering genome-editing systems for therapeutic use.
What is the company stage?
Scribe Therapeutics is clinical-stage and is expanding preclinical programs toward clinical trials.
How much did they raise?
Scribe Therapeutics received more than $25M in non-dilutive funding.
What round is it?
The financing was a non-dilutive CIRM award, not an equity round.
Why did they raise?
Scribe Therapeutics raised to move two CRISPR-based cardiometabolic programs closer to clinical development.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Ingenix raised $14M in June 2026
When was it?
The seed extension was announced on 3 June 2026.
Who are they?
Ingenix builds an AI biological reasoning engine that helps pharma and biotech teams understand complex biology across multiple data types.
Geographical focus?
Ingenix is based in Poland and serves pharma and biotech partners globally.
Why do we include them in the synthetic biology market?
Ingenix fits the AI biology platform category because the company builds software that reasons across biological systems to support biology-driven R&D.
What is the company stage?
Ingenix is at seed-extension stage and is moving deeper into early commercial work with pharma and biotech partners.
How much did they raise?
Ingenix raised €13M, which is approximately $14M for this round.
What round is it?
The financing was a seed extension round led by Sofinnova Partners.
Why did they raise?
Ingenix raised to scale its Biological Reasoning Engine and expand partner access through its Qualified Access Program.
NewLimit raised $435M in June 2026
When was it?
The Series C was reported on 2 June 2026.
Who are they?
NewLimit develops epigenetic reprogramming medicines that aim to restore youthful cell function in age-related diseases.
Geographical focus?
NewLimit is US-based and is initially targeting liver disease and broader age-related conditions.
Why do we include them in the synthetic biology market?
NewLimit fits the cell reprogramming therapeutics category because its medicines activate transcription-factor programs to reprogram the epigenome.
What is the company stage?
NewLimit is late preclinical and is preparing to move its first medicine into human trials.
How much did they raise?
NewLimit raised $435M for this round.
What round is it?
The financing was a Series C round, with a reported valuation of $3.1B.
Why did they raise?
NewLimit raised to launch human trials for a liver medicine and accelerate clinical development of epigenetic reprogramming drugs.
In our synthetic biology market deck, we identify pain points entrepreneurs should prioritize
StrainX Bioworks raised $13M in May 2026
When was it?
The Series A was announced on 25 May 2026.
Who are they?
StrainX Bioworks uses synthetic biology and precision fermentation to produce high-value biomolecules for food, nutraceuticals, and beauty.
Geographical focus?
StrainX Bioworks is India-based and is building around India’s biomanufacturing and ingredient-supply opportunity.
Why do we include them in the synthetic biology market?
StrainX Bioworks fits the precision-fermented biomolecules category because the company engineers strains and fermentation processes to make bio-based ingredients.
What is the company stage?
StrainX Bioworks is at growth and commercial scale-up stage after operating in stealth.
How much did they raise?
StrainX Bioworks raised $13M for this round.
What round is it?
The financing was a Series A round led by Prime Venture Partners and Leo Capital.
Why did they raise?
StrainX Bioworks raised to expand its precision fermentation platform, scale production, and build global partnerships.
Pumpkinseed raised $20M in May 2026
When was it?
The Series A was announced on 5 May 2026.
Who are they?
Pumpkinseed builds a nanophotonic protein-sequencing platform that reads proteins directly for AI biology, biopharma, and biosecurity.
Geographical focus?
Pumpkinseed is US-based and headquartered in Palo Alto, with partners across biopharma and government-backed biology programs.
Why do we include them in the synthetic biology market?
Pumpkinseed fits the protein sequencing and biology data layer category because it creates molecular data used to understand and engineer biology.
What is the company stage?
Pumpkinseed is at Series A stage with early commercial traction through Genentech, DARPA, and BARDA-related work.
How much did they raise?
Pumpkinseed raised $20M for this round.
What round is it?
The financing was a Series A round co-led by NfX and Future Ventures.
Why did they raise?
Pumpkinseed raised to scale deSIPHR from peptide to full-length protein sequencing and expand AI biology partnerships.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
Fermeate raised $2M in April 2026
When was it?
The seed round was announced on 29 April 2026.
Who are they?
Fermeate uses light-controlled gene expression to make industrial precision fermentation more productive without new fermentation infrastructure.
Geographical focus?
Fermeate is US-based and targets global precision fermentation producers that already run industrial biomanufacturing facilities.
Why do we include them in the synthetic biology market?
Fermeate fits the optogenetic fermentation controls category because its platform controls gene expression inside engineered fermentation systems.
What is the company stage?
Fermeate is at seed stage and is scaling an early bioprocess platform with industrial collaborations.
How much did they raise?
Fermeate raised $2M for this round.
What round is it?
The financing was a seed round led by Newfund Capital.
Why did they raise?
Fermeate raised to scale plug-and-play optogenetic fermentation technology that can improve unit economics for existing biomanufacturing facilities.
Clean Food Group raised $6.1M in April 2026
When was it?
The financing was reported on 14 April 2026.
Who are they?
Clean Food Group makes yeast-derived oils and fats that can replace palm oil and conventional fats in food, cosmetics, and pet nutrition.
Geographical focus?
Clean Food Group is UK-based and is expanding production around its Knowsley facility in Merseyside.
Why do we include them in the synthetic biology market?
Clean Food Group fits the yeast-derived oils and fats category because its core product is produced using fermentation instead of conventional agriculture.
What is the company stage?
Clean Food Group is at commercial scale-up stage and is expanding early production capacity.
How much did they raise?
Clean Food Group raised £4.5M, which is approximately $6.1M, plus a separate £700k UK government grant.
What round is it?
The round type was not disclosed in the available funding reports.
Why did they raise?
Clean Food Group raised to expand production of sustainable yeast-derived fats and accelerate commercialization across food, cosmetics, and pet nutrition.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Scala Biodesign raised $16M in March 2026
When was it?
The Series A was announced on 31 March 2026.
Who are they?
Scala Biodesign provides ScalaOS, a hybrid AI-driven protein design platform for enzymes, antibodies, vaccines, biologics, and industrial proteins.
Geographical focus?
Scala Biodesign is Israel-based and sells globally into therapeutic and industrial protein R&D teams.
Why do we include them in the synthetic biology market?
Scala Biodesign fits the AI protein design software category because its platform helps design and optimize biological proteins.
What is the company stage?
Scala Biodesign is at Series A stage and is moving into early commercial expansion.
How much did they raise?
Scala Biodesign raised $16M for this round.
What round is it?
The financing was a Series A round led by Grove Ventures.
Why did they raise?
Scala Biodesign raised to expand ScalaOS globally and accelerate development of protein-based products across therapeutic and industrial applications.
Biographica raised $9.5M in January 2026
When was it?
The seed round was reported on 7 January 2026.
Who are they?
Biographica uses AI and machine learning to identify gene-editing targets that help crop companies develop better traits faster.
Geographical focus?
Biographica is UK-based and works with seed-industry partners, including BASF’s vegetable seeds business.
Why do we include them in the synthetic biology market?
Biographica fits the crop gene-editing design software category because the company identifies genetic targets for engineered crop traits.
What is the company stage?
Biographica is at seed stage and is validating the platform through crop and seed-industry partnerships.
How much did they raise?
Biographica raised £7M, which is approximately $9.5M for this round.
What round is it?
The financing was a seed round led by Faber VC.
Why did they raise?
Biographica raised to expand proprietary data collection, cover more crop traits, and deepen commercial relationships across the seed industry.
Related blog posts
- How strong is fundraising in the synthetic biology market right now?
- The most recent news in synthetic biology
- How large is the synthetic biology market today?
- The evolution of funding activity in synthetic biology
- The main fundraising trends in synthetic biology
- All the funding deals in the synthetic biology market
- The startups that have raised the most funding in synthetic biology
